Almost 2 decades after linking LRRK2 to Parkinson's disease, a vibrant research field has
developed around the study of this gene and its protein product. Recent studies have begun …

Exosomes are emerging as a new type of cancer biomarkers. Exosome is a bilayered nano-
sized vesicle secreted by various living cells in all body fluids. Based on the expanding …

Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic risk factors
for Parkinson's disease (PD). Increased LRRK2 kinase activity is thought to impair lysosomal …

Parkinson's disease (PD) is the second most predominant neurodegenerative disease
worldwide. It is recognized clinically by severe complications in motor function caused by …

Human genetic studies implicate LRRK2 and RAB7L1 in susceptibility to Parkinson disease
(PD). These two genes function in the same pathway, as knockout of Rab7L1 results in …

Parkinson disease (PD) is a prevalent neurodegenerative disease, in which the formation of
misfolded and aggregated α‐synuclein is a key neuropathological hallmark. Recent studies …

No treatments exist to slow or halt Parkinson's disease (PD) progression; however, inhibition
of leucine-rich repeat kinase 2 (LRRK2) activity represents one of the most promising …

In the translation of discoveries from the laboratory to the clinic, the track record in
developing disease-modifying therapies in neurodegenerative disease is poor. A carefully …

Abstract Background Extracellular vesicles (EVs) harbor thousands of proteins that hold
promise for biomarker development. Usually difficult to purify, EVs in urine are relatively …

ABSTRACT Background Mutations in Leucine‐rich repeat kinase 2 (LRRK2) enhance levels
of the autophosphorylated LRRK2 protein and are the most common known cause of …